Breakthrough designation is pivotal It's the final destination that counts Gorf79. In the meantime, this is an opportunity to add more if this final destination is FDA approval. Like it or not. And that's exactly what the market is showing. It's not the bullet points in a press release. It's where the data points. So far, we need a bit more. 5 new patients was not enough.
So if you're long, than the final destination should be what matters. Your whining since April 5th is disturbing, annoying as it changes nothing on the data.